CASI Pharmaceuticals Inc. (CASI)
| Bid | 1.18 |
| Market Cap | 18.75M |
| Revenue (ttm) | 28.54M |
| Net Income (ttm) | -39.26M |
| EPS (ttm) | -2.54 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | -0.79 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 29,162 |
| Avg. Volume (20D) | 102,387 |
| Open | 1.26 |
| Previous Close | 1.30 |
| Day's Range | 1.19 - 1.29 |
| 52-Week Range | 1.10 - 7.67 |
| Beta | 0.63 |
About CASI
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · accessnewswire.com
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial ResultsBEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercial...
1 month ago · accessnewswire.com
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in ChinaBEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commerc...
2 months ago · accessnewswire.com
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial ResultsBEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and comme...